HOME >> BIOLOGY >> NEWS
Novel compound inhibits HIV replication in cell cultures, suggesting possible new type of AIDS drug

Philadelphia, Pa. A compound that inhibits human immunodeficiency virus (HIV) in human immune system cells may eventually provide a new therapeutic approach against AIDS by blocking HIV infection at an early stage. It may also deny the virus a hiding place in the cells from which HIV infection commonly rebounds when current AIDS medications are interrupted.

A research team led by pediatric immunologists at The Childrens Hospital of Philadelphia announced its results in the March 27 Proceedings of the National Academy of Sciences. The research, by Steven D. Douglas, M.D., Jian-Ping Lai, M.D., and Wen-Zhe Ho, M.D., was carried out in human cell cultures.

The compound, CP-96,345, binds to receptors on the surface of monocyte-derived macrophages (MDM), which are immune system cells. These macrophages play an important role in HIV infection because they are a reservoir for the virus. HIV infection remains latent in these cells even while the anti-HIV drug cocktail, highly active antitretroviral therapy, controls the active infection. If the drug cocktail is halted, HIV infection surges back.

"This compound is potentially a very powerful therapy because it may close the door to the virus," said Dr. Douglas, the chief of Immunology at Childrens Hospital and lead author of the article. CP-96,345 interrupts the process by which particular strains of HIV, the R5 strains, enter macrophages through receptors on the macrophages cell surface. Many AIDS researchers are targeting those specific receptors, CCR5 receptors, as a way to block HIV infection in its early stages.

Crucial to the action of CP-96,345 is a naturally produced protein called substance P. First discovered in 1930, substance P is a neurotransmitter, a chemical that carries signals within the brain and elsewhere in the nervous system. Known to be an active transmitter of pain signals, substance P also plays an important role, still under investigation, in the immune system. In 1997, Drs. Doug
'"/>

Contact: John Ascenzi
ascenzi@email.chop.edu
215-590-7332
Children's Hospital of Philadelphia
25-Mar-2001


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/10/2020)... ... March 10, 2020 , ... Cytonus Therapeutics ... Dr. Narasimhan is Senior Vice President of Strategic Initiatives, Portfolio Innovation and Investor ... Directors of Cytonus, we are extremely pleased to welcome Manisha Narasimhan as an ...
(Date:3/5/2020)... ... March 05, 2020 , ... Diagenode, a leading ... Tech (MGI), a subsidiary of global genomics leader BGI Group, today announced a ... States, Europe and Asia Pacific. , Under the terms of the non-exclusive ...
(Date:3/4/2020)... ... March 04, 2020 , ... RoosterBio Inc., ... hMSC bioprocess systems, announces today a significant milestone in the regenerative medicine field ... The patient has been treated by RoosterBio’s pharmaceutical customer with an Investigational New ...
Breaking Biology News(10 mins):
(Date:3/4/2020)... (PRWEB) , ... March 04, ... ... , an industry-leading provider of recombinant antibody products and services, today announced ... customers the flexibility to rapidly express a large number of antibodies at ...
(Date:2/28/2020)... ... 26, 2020 , ... Designed primarily for laboratory and industrial ... controller, thus simplifying setup, streamlining integration, and optimizing workflow. Capable of recording FHD ... Imaging’s new HS Series cameras to be released. The HS Series includes cameras ...
(Date:2/21/2020)... ... ... Join Forrest Brown, Engineering Services Manager – Northeast Region and Jarred Christofaro, Engineering ... session on Wednesday, February 26, 2020 at 1pm EST to learn about:, ... add manufacturing flexibility in the future, especially for CMOs , C&Q Strategy ...
(Date:2/13/2020)... ... February 12, 2020 , ... Arriello ... services, is adopting Veeva Vault Safety™ as part of the company’s ... assessment of data, processing of safety information such as SUSARs and ICSRS, aggregate ...
Breaking Biology Technology:
Cached News: